Unmasking Polycythemia Vera in Long-Standing Essential Thrombocythemia: A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

What this Trial Is About

Researchers are conducting an international multicenter retrospective observational study to understand the progression and outcomes of patients with Essential Thrombocythemia (ET) who carry the JAK2V617F mutation and have developed Polycythemia Vera (PV). The study includes two parts: a nested case-control study and a comparative retrospective cohort study. It aims to compare patients who progressed from ET to PV with those who did not, as well as patients diagnosed with PV without prior ET. The study groups consist of ET-to-PV patients, ET patients who did not progress to PV, and patients diagnosed with de novo PV. Matching is done to ensure comparable groups based on year and age at diagnosis, as well as disease duration. The ET-to-PV cases are identified by the date of PV diagnosis up to the end of 2020, with controls matched to these cases. The de novo PV patients must have been diagnosed by 2020 to allow at least 5 years of follow-up. Participants' medical records will be reviewed retrospectively to gather data up to the baseline and at the time of progression, if applicable. Researchers will analyze clinical outcomes and phenotypic evolution, using the date of PV diagnosis as a key reference point. The study does not involve any interventions or treatments and relies on existing patient data collected from multiple centers. Participation involves no active treatment or visits, focusing on data analysis for up to several years of follow-up.

A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes